fashion -WSS

fashion

author：hotspot 2025-10-02 23:45:02 - browse：25

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

entertainment

WSS

For longer

Liver decline slowed by off

Abbott's new heart device gets FDA advisory panel nod

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Questions and answers about ramping up H5N1 bird flu vaccine

hotspot

fashion

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Report cites 'urgent' need to recruit more diverse clinical trial participants

In age of alternative facts, a scholarly course on calling out crap

Artificial intelligence use in health care faces greater scrutiny in 2024

Supreme Court strikes down use of affirmative action

Scrutiny of post

How to save PrEP access — and even expand it

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Citing H5N1 threat, CDC urges peak flu monitoring this summer

entertainment

H5N1 virus can be tracked in retail milk, scientists say

Congress considering partial increase for doctor pay in Medicare

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

As a primary care physician, here's how I hope to partner with AI

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Abbott's new heart device gets FDA advisory panel nod

knowledge

knowledge

entertainment

entertainment